Kopran's Q4 results show significant growth in profit and sales, but concerns remain

Kopran, a smallcap pharmaceutical company, has recently declared its financial results for the quarter ended March 2024. The company has shown positive performance in terms of profit before tax and after tax, with a growth of 117.23% and 131.6% respectively compared to the same quarter last year. This has led to an increase in net sales by 24.99% year on year.

The company's net sales for the quarter stood at Rs 186.08 crore, the highest in the last five quarters, indicating a positive trend in sales. The earnings per share for the quarter also saw a significant increase, reaching the highest at Rs 3.86 in the last five quarters. This shows that the company has been able to create higher earnings for its shareholders.

However, there are some areas that need improvement for Kopran. The interest cost for the quarter has increased by 15.63% compared to the previous quarter, indicating a rise in borrowings. Additionally, the company's non-operating income, which is 38.40% of the profit before tax, is mainly from non-business activities. This may not be a sustainable business model in the long run.

MarketsMOJO has given a 'Hold' call for Kopran's stock, based on its financial performance in the last quarter. Overall, the company has shown positive growth and profitability, but it is important for them to address the areas of concern to maintain a sustainable business model.